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Pioglitazone is currently undergoing clinical trials for treatment of Alzheimer’s disease (AD). However,
poor brain penetration remains an obstacle to development of the drug for such intended clinical uses. In
this study, we demonstrate that the inhibition of P-glycoprotein (P-gp) significantly increases brain
penetration of pioglitazone, whereas inhibition of breast cancer resistance protein (BCRP) has little effect.
We also investigate the stereoselectivity of pioglitazone uptake in the brain. When mice were dosed with
racemic pioglitazone, the concentration of (1)-pioglitazone was 46.6% higher than that of (-)-pioglitazone
in brain tissue and 67.7% lower than that of (-)-pioglitazone in plasma. Dosing mice with pure
(1)-pioglitazone led to a 76% increase in brain exposure levels compared to those from an equivalent dose of
racemic pioglitazone. Pure (1)-pioglitazone was also shown to have comparable amyloid-lowering
capabilities to the racemic pioglitazone in an in vitro ADmodel. These results suggest that P-gpmay act as a
stereoselective barrier to prevent pioglitazone entry into the brain. Dosing with (1)-pioglitazone instead of
the racemicmixturemay result in higher levels of brain exposure to pioglitazone, thus potentially improving
the development of pioglitazone treatment of AD.
P
eroxisome proliferator-activated receptor-gamma (PPARc) agonists such as rosiglitazone and pioglitazone
have shown promising therapeutic potential against Alzheimer’s disease (AD) in preclinical studies1–5. Both
compounds have been suggested to have a role in regulating several aspects of AD, such as amyloid-b
synthesis, inflammation, energy utilisation and lipid homeostasis6,7. Furthermore, these compounds play a role in
restoration ofmitochondrial activity8–10, offering the added potential of alleviating themitochondrial dysfunction
common in neurodegenerative diseases11,12.
The therapeutic potential of PPARc agonists such as rosiglitazone has been well established in preclinical
studies, although their efficacy has not yet been conclusively demonstrated in clinical trials13–15. Research interest
in PPARc agonists for treatment of AD was heightened after rosiglitazone demonstrated promising treatment
effects in a preliminary clinical trial for AD patients13 and then performed well in a positive phase II clinical trial14.
However, a subsequent phase III clinical trial failed to detect any evidence of rosiglitazone efficacy in the entire
AD patient population enrolled in the study15. To account for this result, the authors hypothesised that effective
levels of rosiglitazone may not be reaching the target tissues in the patient brain15. The authors proposed that the
blockage may be related to the fact that rosiglitazone is a substrate of P-glycoprotein (P-gp), a major drug efflux
transporter present at the blood-brain-barrier (BBB)16. P-gp expression at BBB is up-regulated in rat brain
capillaries by neuroinflammation17, and the authors suggest that a similar condition in AD may further limit
brain exposure to rosiglitazone and obviate its potential therapeutic benefits15. Accordingly, the authors suggest
that other PPARc agonists with higher brain penetration should be investigated.
Pioglitazone is the sole alternative PPARc agonist available in the market; however, pioglitazone also demon-
strates low brain penetration18. Similar to rosiglitazone, pioglitazone showed substantial preclinical promise for
treatment of AD2,5,19. At present, three preliminary clinical trials for pioglitazone in AD patients have been
reported, with contradictory outcomes20–22. A pilot clinical trial assessing pioglitazone’s drug safety profile in
an AD patient population did not detect clinical efficacy20. On the other hand, two preclinical trials performed by
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were given pioglitazone21,22. The discrepancies between the preclini-
cal and clinical results of pioglitazone remain an obstacle to its
development for the treatment of AD, resulting in a critical need
for improved understanding of the factors determining pioglitazone
efficacy. Such knowledge is especially necessary at present, as a new
study from Takeda is currently recruiting 5800 subjects for a 5-year-
long, phase III clinical trial to assess the therapeutic potential of
pioglitazone in AD23.
Given the structural similarity of rosiglitazone and pioglitazone,
we hypothesised that drug efflux transporters present at the BBB also
limit brain penetration of pioglitazone. At present, no study has
successfully addressed this factor. Therefore, in this study, we inves-
tigated the two most relevant drug efflux transporters, P-gp and
breast cancer resistance protein (BCRP)24, as potential barriers to
brain penetration of pioglitazone. Our in vivo experiments dem-
onstrate that inhibition of P-gp leads to a significant although not
substantial increase in the levels of pioglitazone in brain tissue, indi-
cating the involvement of P-gp in limiting pioglitazone brain pen-
etration. Because P-gp had previously shown clinically relevant
stereoselectivity in its activity25,26, we further investigated the two
stereoisomers of pioglitazone to explore stereoselectivity of brain
uptake. Our findings show higher levels of (1)-pioglitazone in brain
tissue than (-)-pioglitazone after a single dose of racemic pioglitazone
in mice. We concluded that administration of purified (1)-pioglita-
zone rather than a racemic mixture may significantly increase brain
tissue exposure in mice, and therefore represents a feasible strategy
for overcoming low brain penetration of pioglitazone on a clinical
level. Additionally, we demonstrated that (1)-pioglitazone has amy-
loid-lowering capabilities in an AD in vitro model comparable to
those of the racemic pioglitazone. Thus, higher drug exposure of
(1)-pioglitazone in the brain may improve clinical efficacy of the
drug. Our findings represent an original contribution to the develop-
ment of pioglitazone as a therapeutic treatment of AD and will be
useful to research scientists and clinicians involved in pioglitazone
phase III clinical trials for AD patients.
Results
Quantitative measurement of pioglitazone in biological samples
using UPLC-MS/MS. A UPLC-MS/MS method was developed to
quantify pioglitazone in both sample conditions (plasma and brain
tissue). Multiple-reaction-monitoring (MRM) analyses were carried
out using optimised m/z transitions for both pioglitazone (357 to
134) and rosiglitazone (358 to 135). The optimised operating con-
ditions for mass spectrometry were: curtain gas, 15 psi (nitrogen);
turbo gas temperature, 550uC; ion spray voltage, 5,500 V; nebulising
gas, 40 psi; turbo gas, 40 psi; declustering potential, 54 V; entrance
potential, 9 V; collision energy, 40 eV; collision cell exit potential,
4 V. The optimised retention times (RT) for pioglitazone and rosig-
litazone were determined to be 0.72 minutes and 0.61 minutes,
respectively. Five calibration samples were used to build calibration
curves for both plasma and brain-tissue samples. Calibration curves
were constructed from analyte-to-internal standard (IS) peak-area
ratios. Weighted 1/x quadratic regression produced linear plots for
plasma and brain samples over concentration ranges of 500–
4000 ng/mL (r2 5 0.9995) and 50–3000 ng/mL (r2 5 0.9998),
respectively. Pioglitazone concentrations for different samples
types were then determined based on the respective calibration
curves.
In vivo investigation of P-gp and BCRP contributions to limited
brain penetration of pioglitazone. All animals were pre-treated
with the respective drug transporter inhibitor(s) 30 minutes before
administration of pioglitazone. Thirty minutes after treatment with
pioglitazone, all animals were sacrificed and plasma and brain
samples were collected. No significant differences were found in
pioglitazone plasma concentrations among all four treatment
groups (Figure 1A). The brain-to-plasma ratios of pioglitazone
concentrations were used to assess penetration of brain tissue.
Mice that were given vehicle as pre-treatments (the control group)
had a pioglitazone brain-to-plasma concentration ratio of 10.65 6
1.25%, which did not increase significantly when mice were pre-
treated with Ko143 (BCRP inhibitor). However, pre-treatment
with LY335979 (P-gp inhibitor) increased the pioglitazone brain-
to-plasma concentration ratio significantly—although not substantially—
by 16.92%, reaching 12.45 6 1.15% (P 5 0.0287), while pre-treatment
with combined LY335979 1 Ko143 also increased this ratio by
20.82%, reaching 12.87 6 1.56% (P 5 0.0235). No significant
difference was observed between the brain-to-plasma ratios of the
latter two treatment groups. Data on brain-to-plasma ratios are
summarised in Figure 1B.
Investigation of stereoselectivity of pioglitazone brain penetra-
tion using chiral HPLC-MS/MS. Both (1)-pioglitazone and (-)-
pioglitazonewere successfully separated using an analytical reversed-
phase chiral HPLC column (Chiralcel OD-R 10 mm particle size,
Figure 1 | All animals were pre-treated with either the vehicle or the respective drug-transporter inhibitor (n5 6 for each treatment group) 30minutes
prior to drug treatment. Plasma and brain samples were then collected from the animals 30 minutes after pioglitazone treatment. (A) Pioglitazone levels
in plasma samples harvested frommice given i.p. pioglitazone with or without pre-treatment of LY335979 (P-gp blocker) and/or Ko143 (BCRP blocker).
(B) Brain-to-plasma ratios of pioglitazone concentrations calculated for each mouse given i.p. pioglitazone with or without pre-treatment of LY335979
and/or Ko143. Error bar represents one SD. * P 5 0.0287 and ** P 5 0.0235 when compared against vehicle-only pre-treatment group.
www.nature.com/scientificreports
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4.6 mm (i.d.) 3 250 mm) with retention times (RTs) of appro-
ximately 28.00 minutes and 31.50 minutes, respectively. Chro-
matograms for both brain-tissue and plasma samples from all
three mice are shown in Figure 2. The (1)-pioglitazone levels were
consistently 46.6% higher than those of (-)-pioglitazone in brain-
tissue samples. The opposite trend was observed in plasma
samples; (1)-pioglitazone levels were consistently 67.7% lower
than those of (-)-pioglitazone. No difference was found between
the amount of (1)-pioglitazone and (-)-pioglitazone in control
brain and plasma samples spiked with racemic pioglitazone.
Purification and identification of (1)-pioglitazone. (1)-pioglita-
zone was successfully fractionated from the racemic mixture using
semi-preparative HPLC. Purity was established by analysing three
separate samples taken from the purified (1)-pioglitazone powder,
which all showed .98.0% purity (n 5 3, 98.08%, 98.12%, and
98.94%). The identity of (1)-pioglitazone was confirmed by
measuring the optical activity of the purified powder dissolved in a
solution of 90% acetonitrile and 10% isopropanol, supplemented
with 0.1% acetic acid. Solvent alone was used as a zero reference
before optical activity was measured for ten separately prepared
(1)-pioglitazone solutions. Specific rotation in degrees ([a]lT) for
1.11 mg/mL (1)-pioglitazone solution was calculated to be
10.8198 cm2/g, which confirmed the identity of purified powder
to be the (1)-pioglitazone stereoisomer.
In vivo comparative studies of racemic and (1)-pioglitazone drug-
distribution profiles. Our established UPLC-MS/MS method was
used to quantify pioglitazone concentrations in plasma and brain
samples harvested at different time points (1, 2, 4, 6, and 8 hours)
after mice were given either racemic pioglitazone or (1)-pioglita-
zone. The profiles of mean plasma concentrations or mean brain
concentrations of pioglitazone versus time are shown in Figure 3A
and Figure 3B, respectively. Mice treated with racemic pioglitazone
showed a significantly higher plasma concentration maximum
(Cmax, 53.53 6 8.07 mg/mL) than did mice treated with (1)-
pioglitazone (39.92 6 6.20 mg/mL, P 5 0.0442). The peak time
(Tmax) of plasma pioglitazone for mice from both treatment
groups was 1 hour after drug administration. The area-under-the-
curve (AUC)0–‘ values of plasma pioglitazone were 2.62 3
105 mg?hour/L and 2.74 3 105 mg?hour/L for mice that received
racemic and (1)-pioglitazone, respectively. In contrast, the brain
Cmax was not significantly different between mice that received the
racemic pioglitazone (4.88 6 0.34 mg/mL) or the (1)-pioglitazone
(5.07 6 0.38 mg/mL). However, in mice that received (1)-
pioglitazone, the brain pioglitazone concentration was significantly
higher at 4, 6 and 8 hours after drug administration than mice
treated with racemic pioglitazone, suggesting slower clearance of
the (1)-isomer from the brain. The brain AUC0–‘ for mice that
received (1)-pioglitazone (4.00 3 104 mg?hour/L) was also
remarkably higher (76%) than that for mice treated with racemic
pioglitazone (2.27 3 104 mg?hour/L).
Relative amyloid-lowering capabilities of (1)-pioglitazone and
racemic pioglitazone in CHO-APP695. Forty-eight hours after
seeding incubation, extracellular amyloid-b42 levels were increased
significantly in CHO-APP695 (143.8%) compared to CHO-WT
cells. This increase in extracellular amyloid-b42 was reduced
significantly by treatment with either the racemic pioglitazone or
(1)-pioglitazone (P 5 0.0025 and P 5 0.0016, respectively, when
compared with the non-treated CHO-APP695). The treatment effect
of (1)-pioglitazone was nullified by co-administration of PPARc
selective blocker (T007), and a similar extent of nullification was
observed with treatment of the racemic pioglitazone, although this
treatment reversal effect did not reach the significant threshold. All
data are summarised in Figure 4.
Discussion
Themain aim of this study is the exploration of factors thatmay limit
brain penetration of pioglitazone, which is currently being investi-
gated in clinical trials as a therapeutic agent for neurodegenerative
diseases. Specifically, we focused our efforts on effects of drug efflux
transporters at the BBB. AD transgenic mouse models are not ideal
for our in vivo experiments because the BBB is compromised in AD
transgenic mice27. An earlier clinical study indicated that no general-
ised abnormality existed in the BBB in AD patients28. A more recent
study also indicated no evidence for additional BBB P-gp dysfunc-
tion in AD patients with microbleeds29. Therefore, in order to simu-
late the BBB of AD patients, it was appropriate to employ a mouse
model with an intact BBB to investigate drug distribution in the brain
for the objective to treat AD. For these reasons, healthy C57BL/6
mice were used as models of choice in our pioglitazone brain/plasma
distribution study.
In this study, we observed significant, although not substantial
increases in brain penetration of pioglitazone when mice were pre-
treatedwith P-gp inhibitor (LY335979) or a combination of P-gp and
BCRP inhibitors (Ko143). However, pre-treatment with BCRP
Figure 2 | (A) Chiral separation of (1)-pioglitazone and (-)-pioglitazone in brain samples of mice administered with racemic pioglitazone;
chromatogram in box shows (1)-pioglitazone and (-)-pioglitazone in blank brain sample spikedwith racemic pioglitazone. (B) Chiral separation of (1)-
pioglitazone and (-)-pioglitazone in plasma samples of mice administered with racemic pioglitazone; chromatogram in box shows (1)-pioglitazone and
(-)-pioglitazone in blank plasma sample spiked with racemic pioglitazone.
www.nature.com/scientificreports
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inhibitor alone did not improve the brain penetration of pioglita-
zone. This shows that BCRP inhibition alone has no effect on brain
penetration of pioglitazone at the dose used in this study; however, it
may have synergistic effects when functioning in concordance with
P-gp.
Mice that did not receive any drug-transporter inhibitor showed a
brain-to-plasma pioglitazone ratio of 10.65%. To the best of our
knowledge, this is the first study to investigate brain penetration of
pioglitazone using C57BL/6 mice. Our observed brain penetration of
pioglitazone is in agreement with previous studies using other ani-
mals, which have reported low pioglitazone brain penetration in
general18,30. One study observed that cerebral spinal fluid (CSF) con-
centration of pioglitazone in monkeys was less than 3% of plasma
concntrations30. Another study reported that approximately 18% of
serum pioglitazone is found in the CSF of rats, dogs, and monkeys18.
We observed that brain penetration of pioglitazone increased
upon pre-treatment with P-gp inhibitor or combined P-gp 1
BCRP inhibitors but not with BCRP inhibitor alone. This study is
the first to investigate the contribution of P-gp and BCRP drug efflux
transporters to the limitation of pioglitazone brain penetration. Our
findings are comparable to another study that investigated the
involvement of transporters at the human placental apical mem-
brane on the penetration of rosiglitazone, a close structural analogue
of pioglitazone. Having investigated effects of three drug efflux trans-
porters (P-gp, BCRP and Multidrug Resistance Protein, MRP1) at
the human placental apical membrane, Weiss et al. also found that
rosiglitazone was predominantly transported by P-gp24. We noted a
small rise from 16.92 to 20.82% in the brain-plasma ratios after
treatment with the P-gp inhibitor or P-gp 1 BCRP inhibitors.
Many possible reasons exist for the small observed increases in
brain-plasma ratios after pre-treatment with the transporter inhibi-
tors. One possible reason is that we only measured one time-point of
the brain and plasma concentrations at 30 minutes after pioglitazone
administration and calculated the corresponding brain-plasma con-
centration ratio. At that particular time-point, the effect of P-gp
inhibition on the brain-plasma distribution may not be very evident.
This postulation is supported by the findings regarding the stereo-
selective distribution of the drug in Figure 3, which show that the
difference in the brain concentration after administration of the
racemic and (1) pioglitazone is only observed after the peak con-
centration (Cmax) between 1–2 hours, i.e., after the absorption phase.
This means that the stereoisomers may behave differently in the
elimination phase than in the absorption phase, when it is cleared
from the brain. P-gp is known to be stereoselective in activity25,26. It is
possible that if the brain-plasma ratios had been obtained after the
Cmax, the P-gp inhibition may show a greater influence on the ratios.
However, our research objective in this preliminary experiment was
simply to investigate whether pioglitazone is a substrate of P-gp and/
or BCRP and not the extent of inhibition by P-gp.
Our findings clearly indicate that pioglitazone is a substrate of P-
gp, which may contribute to the low brain exposure of pioglitazone
observed in this and in other studies18,30. The low brain drug exposure
is possibly an obstacle to the development of pioglitazone as a treat-
ment of AD considering the fact that rosiglitazone’s failure to reach
therapeutic levels in brain tissue and thus its phase III AD trial failure
was attributed to interactions with P-gp15. Co-administration of pio-
glitazone with P-gp regulators is a potential dosing strategy to
enhance brain penetration and therapeutic effects of pioglitazone
for treating AD. However, this dosing strategy is severely limited
for a chronic disease such as AD by the poor solubility and nonspe-
cific toxicity of even third-generation P-gp inhibitors31. In our
attempt to devise a better strategy for enhancing pioglitazone brain
penetration, we focused on the stereoselectivity of pioglitazone brain
partitioning instead.
Remarkably, (1)-pioglitazone levels were clearly higher than (-)-
pioglitazone levels in the brains of mice dosed with racemic piogli-
tazone, and the opposite trend was observed in the plasma. This
Figure 3 | (A) Pioglitazone concentrations versus time plot for plasma samples harvested frommice given either racemic pioglitazone (AUC0–‘5 2.623
105 mg?hour/L) or purified (1)-pioglitazone (AUC0–‘ 5 2.74 3 10
5 mg?hour/L). (B) Pioglitazone concentrations versus time plot for brain samples
harvested frommice given either racemic pioglitazone (AUC0–‘ 5 2.27 3 10
4 mg?hour/L) or purified (1)-pioglitazone (AUC0–‘ 5 4.00 3 10
4 mg?hour/
L). Error bar represents one SD.
Figure 4 | Extracellular amyloid-b42 levels in culture media samples
harvested from both CHO-WT and treated or non-treated CHO-APP695
following 48 hours of post-seeding incubation. Error bar represents one
SD. * P 5 0.0002 when compared against CHO-WT, ** P 5 0.0025 when
compared against non-treated CHO-APP695, *** P 5 0.0016 when
compared against non-treated CHO-APP695, **** P 5 0.0206 when
compared against CHO-WT.
www.nature.com/scientificreports
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result offers a potentially superior AD treatment strategy that uses
(1)-pioglitazone, as this stereoisomer’s higher presence in the brain
suggests that more (1)-pioglitazone can be distributed to the brain
and/or be retained for longer duration in the brain. Additionally, the
lower presence of (1)-pioglitazone in plasma may translate to fewer
undesirable drug effects or drug-induced toxicity in peripheral tissue
organs. This combination of pharmacokinetic and target-delivery
qualities makes (1)-pioglitazone a very promising candidate for
development as a treatment of brain diseases such as AD.
Naturally, the next course of action is the determination of
whether administration of purified (1)-pioglitazone can result in a
higher presence of pioglitazone in the brain compared to the racemic
form of pioglitazone currently available in the market. We hereby
report for the first time that total pioglitazone exposure in brains of
mice treated with (1)-pioglitazone is higher (176%) than mice
given racemic pioglitazone. Nonetheless, the total presence of piogli-
tazone in plasma of mice given (1)-pioglitazone was only 4% higher
than that in mice fed with racemic pioglitazone. This result clearly
demonstrates the brain-targeting property of (1)-pioglitazone,
which offers two advantages to therapeutic application. First,
increasing brain penetration of pioglitazone results in more drug
compound crossing the BBB from the same dose given to the patient,
thus therapeutic levels required for pioglitazone to exert its treatment
effects in brain tissue are more easily reached. Second, the higher
brain-targeting ability of (1)-pioglitazone allows a lower dose of
pioglitazone to be given to AD patients to achieve the same thera-
peutic effect, thereby minimising undesirable drug effects or drug-
induced toxicities in unintended organs. Our preliminary data also
demonstrate that (1)-pioglitazone is comparable to racemic piogli-
tazone in its amyloid-lowering effect in an AD in vitro model
(Figure 4). It should be noted that amyloid-lowering capacity is
not the most directly relevant therapeutic effect of pioglitazone.
The anti-inflammatory effect and restoration of mitochondrial dys-
function by pioglitazone are likely also involved in its potential thera-
peutic effects against AD6,9,10. However, amyloid-b disposition is one
of the most established downstream biomarkers in AD pathology,
and CHO-APP695 is an established amyloidogenic cellular model10.
Thus, it is convenient and logical, although not certain, to use amy-
loid-lowering capacity to gauge the therapeutic potential of racemic
mixture and the (1)-isomer using this in vitro model.
In conclusion, this study offers several novel findings that are
valuable in drug development of pioglitazone for AD therapy, and
our report is especially timely because pioglitazone is currently being
investigated in clinical trials for several neurodegenerative dis-
eases23,32.We demonstrate the role of P-gp as a barrier to pioglitazone
reaching the brain, which has been discussed as a critical reason for
the failure of rosiglitazone in phase III AD clinical trials15. We suc-
cessfully devised a novel strategy to tackle poor brain penetration of
pioglitazone by dosing with purified (1)-pioglitazone. However,
further characterisation is needed to pursue (1)-pioglitazone as a
therapeutic molecule for AD; in particular, the clinical safety and
efficacy profiles remain to be established. Nevertheless, based on
the present findings, enhanced brain retention of pioglitazone
through administration of the (1)-isomer improves the promise of
pioglitazone as an effective drug candidate for treating AD.
Methods
Chemicals. Ko143 (a selective inhibitor of BCRP) was purchased from Enzo Life
Sciences (Lausen, Switzerland). LY335979 (a selective inhibitor of P-gp) was a
generous gift from Eli Lilly and Company. T0070907 (T007, specific inhibitor of
PPARc receptor) was purchased fromCaymanChemical Company (AnnArbor,MI).
Pioglitazone and rosiglitazone (internal standard, IS) were purchased from Cell
Molecular Pharmaceutical R&D (Xi’an, China). All other reagents used were
analytical grade.
Animals. In total, 64 adult male C57BL/6 mice (10–12 weeks of age) with body
weights ranging between 23 and 28 g were obtained from the Centre for Animal
Resources (CARE), National University of Singapore. The mice were housed in
groups (maximum of 5 mice per cage) under standard conditions of humidity,
temperature and 12-h light/dark cycle with ad libitum access to food and water. All
mice were maintained under constant conditions for 4 days prior to experiments. All
animal experiments were conducted in accordance with Singapore National Advisory
Committee on Laboratory Animal Research (NACLAR) guidelines and approved by
NUS Institutional Animal Care and Use Committee (IACUC).
In vivo investigations of P-gp and BCRP contributions to limiting brain
penetration of pioglitazone. A total of 24 mice were divided into four treatment
groups (n 5 6), where three groups received pre-treatment of efflux pump inhibitors
(P-gp inhibitor LY335979, BCRP inhibitor Ko143, and a combination of LY3359791
Ko143) and one group received vehicle pre-treatment as a control. All test
compounds (pioglitazone, LY335979, and Ko143) were dissolved in Milli-Q water
using 1% DMSO as co-solvent. Pre-treatments of LY335979 (25 mg/kg), Ko143
(5 mg/kg) or a combination of both were given in a single intra-peritoneal (i.p.)
injection 30 minutes before pioglitazone administration (i.p. injection, 30 mg/kg). At
these selected doses, both LY335979 and Ko143 exhibited 50% inhibition of P-gp33
and BCRP34, respectively, in previous studies using mice, thus allowing previous
effects to be compared with those in this study. Following another 30 minutes after
pioglitazone administration, all mice were sacrificed by CO2 euthanasia and their
blood samples were collected via cardiac puncture into Eppendorf tubes
supplemented with heparin. Transcardial perfusion with saline was then performed
on the sacrificed mice to remove traces of blood from organs before the whole brain
tissues were harvested. All biological samples were kept on ice immediately after
collection. Blood samples were centrifuged at 4000 g for 10 minutes and plasma
samples (supernatant) were then carefully transferred into clean Eppendorf tubes.
Plasma and all tissue samples were stored at 280uC until analysis. Plasma
pioglitazone concentrations and brain-to-plasma pioglitazone ratios in samples
harvested from all four treatment groups were used to evaluate the effects of pre-
treatments with drug efflux transporter inhibitor(s) on distribution of pioglitazone.
Comparisons of data between groups were carried out using two-tailed independent
t-test with Welch’s correction, and statistical significance was defined as P , 0.05.
Sample preparation for quantitative measurement of pioglitazone in biological
samples. All samples were thawed and kept on ice. Brain-tissue samples were
homogenised withMilli-Qwater in a ratio of 1 part tissuemass to 1 part water. Plasma
and brain homogenate were then diluted 10-fold and 3-fold with Milli-Q water,
respectively. 95 mL of diluted sample was transferred into a clean Eppendorf tube, and
rosiglitazone (2.5 ng in 5 mL ofDMSO)was added as an internal standard (IS) to each
sample. 300 mL of methanol was then added to each tube to initiate protein
precipitation for extraction of the analyte. All mixtures were vortex-mixed at high
speed for 5 minutes and centrifuged at 14000 g (20 minutes at 4uC) to pellet the
precipitated protein and sample debris. Supernatants were then transferred into
injection vials for subsequent analysis using ultra performance liquid
chromatographic system coupled with tandem mass spectrometer (UPLC-MS/MS).
For calibration standards, blank plasma and tissue homogenates (spiked with 100,
500, 1000, 2500, 5000, and 10000 ng/mL pioglitazone) were prepared in a similar
manner and used to build a calibration curve for each sample type.
Instrument operating conditions of UPLC-MS/MS and data processing. Liquid
chromatographic separations were performed using the Waters Acquity UPLC
system fitted with Acquity UPLC BEH C18 1.7 mm, 2.1 (i.d.) 3 50 mm column
(Waters Corp., MA, USA). Temperatures of column and autosampler were
maintained at 45uC and 10uC, respectively. The mobile phases consisted of 1% (v/v)
formic acid in Milli-Q water (solvent A) and 1% (v/v) formic acid in acetonitrile
(solvent B) delivered at 0.6 mL/minute. The elution conditions used were as follows:
isocratic at 20% solvent B (0–0.2 minute), gradient of 20% to 90% solvent B (0.2–1.5
minute), isocratic at 95% solvent B (1.5–1.8 minute), isocratic at 0.1% solvent B (1.8–
2.2 minute) and isocratic at 20% solvent B (2.2–2.5 minute).
API 3200 triple quadrupole mass spectrometer (AB SCIEX, MA, USA), operating
in positive electrospray ionisation mode, was used for detection of pioglitazone and
rosiglitazone (IS). Multiple-reaction-monitoring (MRM) method was used to mea-
sure both pioglitazone (target compound) and rosiglitazone (IS). The following MS
operating conditions were optimised: curtain gas, turbo gas temperature, ion spray
voltage, nebulising gas, turbo gas, declustering potential, entrance potential, collision
energy, and collision cell exit potential. Integration of peak areas and data processing
were carried out using Analyst version 1.4.2 software (AB SCIEX). Analyte/IS peak
area ratios were used to construct calibration plots for different tissue sample types,
which were then used to determine concentrations of pioglitazone in experimental
samples.
Exploratory investigation of stereoselectivity in pioglitazone brain penetration
using chiral HPLC-MS/MS. Using the same approach described in the in vivo
experiment, we investigated the differential distribution of (1)-pioglitazone and (-)-
pioglitazone in brain and plasma of mice (n 5 3) that received vehicle-only pre-
treatment and racemic pioglitazone i.p. injection (30 mg/kg). Brain and plasma
samples were harvested 30minutes after administration of pioglitazone (i.p. injection,
30 mg/kg), in a similarmanner to that described above. Stereoisomers of pioglitazone
were separated by reversed phase chiral high performance liquid chromatographic
(HPLC) column. Brain and plasma samples from mice, as well as blank brain and
plasma samples spiked with racemic pioglitazone, were subjected to chiral HPLC
separation and quantified using tandem MS. Chiral liquid chromatographic
www.nature.com/scientificreports
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separations were performed using Agilent 1200 HPLC system (Agilent Technologies,
CA, USA) fitted with Chiralcel OD-R 10 mm particle size, 4.6 mm (i.d.) 3 250 mm
analytical column (Chiral Technologies Europe, Illkirch-Graffenstaden, France).
Temperatures of the column and autosampler were maintained at 25uC. A mobile
phase consisting of 60% (v/v) methanol in MilliQ water was delivered at 1.0 mL/
minute under the isocratic elution mode. Detection and quantitation of pioglitazone
was carried out using API 3200 MS (AB SCIEX) according to tandem MS operating
conditions described above. The ratios of both stereoisomers relative to one another
were used to determine their relative distribution in each sample type.
Purification and identification of (1)-pioglitazone from racemic mixture.
Purification of (1)-pioglitazone was carried out using theHPLC system coupled with
a UV detector and automated fraction collector. The system consisted of a Shimadzu
LC-10AT pump, SCL-10A system controller and FRC-10A fraction collector
(Shimadzu Corporation, Kyoto, Japan). The chiral column used was a Chiralpak IA
5 mm particle size, 10 mm (i.d.) 3 250 mm semi-preparative column (Chiral
Technologies Europe, Illkirch-Graffenstaden, France). For every round of collection,
250 mL of pioglitazone solution (5 mg/mL) was injected and separated using isocratic
mobile phase elution (90% acetonitrile and 10% isopropanol, supplemented with
0.1% acetic acid), and detection wavelength was set at 266 nm to monitor analyte
peak elution. HPLC elution flow rate was set to 2 mL/minute and temperature was
maintained at 40uC. Racemic pioglitazone was dissolved in solvent of a similar
composition to the mobile phase to prepare the solution for injections. The retention
time (RT) for (1)-pioglitazone was approximately 15.00 minutes with peak width of
2minutes. The RT of (-)-pioglitazone was 40.00minutes, evidently separable from the
(1)-isomer, therefore allowing collection of the latter isomer. The collected fraction
was then dried using a rotary evaporator to obtain purified powder of (1)-
pioglitazone. Purity of (1)-pioglitazone was then examined by re-constituting the
powder in mobile phase solvent and analysing the re-constituted solution using the
previously established chiral HPLC separation coupled with MS detection (API 3200
MS, AB SCIEX) using MRM method (m/z transitions of 357 to 134 for pioglitazone
detection). The identity of purified (1)-pioglitazone was confirmed by measuring its
optical activity using a DIP-1000 Spectropolarimeter (Jasco Inc., MD, USA). Optical
rotation measurements were performed in pioglitazone solution (1.11 mg/mL) in a
10-mm cell and were measured at a wavelength of 589 nm and temperature of 26uC.
Specific rotation (cm2/g) was calculated using the equation [a]lT 5 a/L * c (where
[a]lT is the specific rotation, a is the observed rotations in degrees, L is the cell path in
dm, and c is the sample concentration in g/100 mL).
In vivo comparative studies of racemic and (1)-pioglitazone drug-distribution
profiles.A total of forty mice were split into two treatment groups (n 5 20), with one
group receiving a single dose of the racemic pioglitazone (30 mg/kg, p.o.) and another
group receiving the purified (1)-pioglitazone (30 mg/kg, p.o.). Both compounds
were dissolved in Milli-Q water using 1% DMSO as co-solvent. Following oral
administration of the test compounds, mice from both treatment groups were split
again into five subgroups (n 5 4), and mice belonging to different subgroups were
sacrificed at different time points (1 hour, 2 hours, 4 hours, 6 hours, and 8 hours
after oral dosing). All mice were sacrificed by CO2 euthanasia and blood samples were
taken via cardiac puncture. Blood samples were then centrifuged at 4000 g (10
minutes) to collect the plasma. Whole brains were collected following transcardial
perfusion with saline to remove blood from organs. Sample treatment for
measurement of pioglitazone in plasma and brain samples using UPLC-MS/MS was
similar to the procedure described above. Pioglitazone concentrations versus time
graphs were constructed for both brain and plasma samples, and area under curve
(AUC) for both (1)-pioglitazone and racemic pioglitazone were then used to assess
each tissue’s exposure to pioglitazone. AUC was calculated from time 0 hour to
infinity (AUC0–‘) for both types of samples using the trapezoidal rule. Comparisons
of pioglitazone concentrations in different sample matrices between the two
treatment groups were performed using two-tailed independent t-test with Welch’s
correction, and statistical significance was defined as P , 0.05.
Culture conditions for the CHO-APP695 cell line, an AD in vitro model. CHO
(Chinese hamster ovary) cells stably transfected with mouse APP 695 (CHO-APP695)
were used as theAD in vitromodel in this experiment. CHO-APP695 and thewild type
(CHO-WT) were kindly provided by G. S. Dawe (National University of Singapore,
Singapore). Both cell lines were incubated at 37uC in the presence of 5% CO2 for all
cell culture work. Cell lines were maintained in DMEM culture medium (Sigma
D1152) containing 10% FBS and supplemented with 100 units/mL of penicillin and
100 mg/mL of streptomycin.
Comparing efficacies of (1)-pioglitazone and racemic pioglitazone on lowering
extracellular amyloid-b42. When cells were used for experiments, both CHO-
APP695 and CHO-WT were standardised at third passage and harvested for seeding
when the cells were at log-phase growth. Cells were seeded (n 5 7) on 24-well cell
culture plates at 13 105 cells/well in 0.5 mL of culturemedium. To evaluate amyloid-
lowering effects of (1)-pioglitazone and racemic pioglitazone on extracellular
amyloid-b42 levels, additional groups (n 5 7) of CHO-APP695 treated with (1)-
pioglitazone, (1)-pioglitazone 1 T007, racemic pioglitazone, and racemic
pioglitazone 1 T007 were also seeded. A concentration of 10 mM was used for all
treatment compounds because this concentration has been shown to have no
significant impact on cellular proliferation rates of CHO-APP695 andCHO-WTwhen
cultured under similar experimental conditions in our previous study10. Upon
completion of seeding after 24 hours, the culture medium in each well was replaced
with 0.5 mL of freshmedium. Seeded cells were incubated further for 48 hours before
the culture medium was individually harvested. Harvested samples were briefly
centrifuged (800 g) for 5 minutes at 4uC before supernatants were transferred into
clean 1.8-mL cryogenic vials and snap frozen in liquid nitrogen. All harvested samples
were stored at 280uC until analysis.
Measurement of extracellular amyloid-b42. Amyloid-b42 levels in culture media
were harvested 48 hours after seeding incubation and were quantitatively measured
using colorimetric sandwich ELISA kits according to the protocols provided by the
manufacturer (#SIG-38954 and #SIG-38956 from Covance, Princeton, NJ).
Undiluted culture medium was used to detect amyloid-b42. Non-normalised data
were then statistically compared using two-tailed independent t-test with Welch’s
correction and statistical significance was defined as P , 0.05. All absorbance
readings were measured using a Tecan Infinite M200 microplate reader (Tecan,
Switzerland).
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